Detailed financial terms were not disclosed

In addition, such epitopes may provide the opportunity to create newintellectual property, even in more heavily investigated areas."We are very pleased to expand further our successful and longstandingcollaboration with Allergan. We believe that combining the capabilities ofour two organizations and enlarging both the research and commercial scopewill enhance our ability to create value for our shareholders," said LoicMaurel, CEO of ExonHit Therapeutics.The agreement provides for revised commercial terms. It expandsAllergan's rights when sublicensing compounds discovered in the course of thecollaboration with ExonHit. ExonHit will also be paid royalties on future sales.Detailed financial terms were not disclosed.About ExonHit TherapeuticsExonHit Therapeutics is the world's leader in the analysis of alternativeRNA splicing, a process which when deregulated plays a key role in the onsetof various diseases.ExonHit Therapeutics has a multi-component commercial strategy to capturethe maximum value from its leadership in alternative splicing. The Company isalready generating revenues from a new generation of microarrays,SpliceArray(TM) family of products that enable life science researchers todetect crucial disease-associated information.

These products are marketedworldwide in conjunction with Agilent and Affymetrix. In the field ofdiagnostics, ExonHit Therapeutics has a major collaboration with bioMerieuxto develop completely novel predictive blood-based cancer diagnostics, whichcould play a key role in improving the treatment of breast cancer and othermajor cancers.In parallel, ExonHit Therapeutics is developing its own therapeuticpipeline in the field of neurodegenerative diseases and cancer. ExonHit Therapeutics also has a strategicpartnership with Allergan, to discover and develop new therapeutics in theareas of pain, neurological diseases and ophthalmology. This collaborationprovides on-going research funding to ExonHit.Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S.facility in Gaithersburg, Maryland. The Company is listed on Alternext ofEuronext Paris (ISIN: FR0004054427; ticker: ALEHT) since November 17, 2005.For more information, please visit http:// press release includes only summary information and does not purportto be comprehensive. The projections, forecast and estimates of ExonHitTherapeutics which may be contained herein are for illustrative purposes onlyand are based on management's current views and assumptions. Suchprojections, forecast and estimates involve known and unknown risks anduncertainties, as described at Section 4.2 "Facteurs de risque" (RiskFactors) of the Document de Base available on ExonHit Therapeutics' website( http://), that may cause actual results, performance orevents to differ materially from those anticipated in the summary information.In addition, ExonHit Therapeutics, its shareholders, and its affiliates,directors, officers, advisors and employees have not verified the accuracyof, and make no representations or warranties in relation to, statisticaldata or predictions contained in this press release that were taken orderived from third party sources or industry publications, and suchstatistical data and predictions are used in this press release forinformation purposes only.Finally, this press release may be drafted in the French and Englishlanguages.

In an event of differences between the texts, the French languageversion shall prevail. A localized region on the surface of an antigen that is capable ofeliciting an immune response and of combining with a specific antibody tocounter that responseSOURCEExonHit Therapeutics SAContacts: ExonHit Therapeutics: Loic Maurel, CEO, Tel: 33-1-58-05-47-00.Philippe Rousseau, CFO, .. As a preface, this article was originally written for a debate final. It ran a little long, but I liked it as it was and didn't feel the need to cut any points.This January, the Baseball Hall of Fame will announce its 2010 inductees, and until then, there will be much debate as to who is worthy and who is not. I would like to analyze each of the candidates, but that doesn’t seem like a plausible task in a four to eight minute time slot.So, instead, I’ll will drop defending candidates, such as Bert Blyleven, or arguing against candidates, such as Andre Dawson, in which the cases are entirely based on numbers, and will stick to candidates with both a numerical and a moral side.And so, with this in mind I would like to present the cases for Pete Rose, Joe Jackson, Mark McGwire, and Dave Parker. Pete Rose has a clear case for enshrinement. He is the all-time leader in career hits, won both a Most Valuable Player and a Rookie of the Year award, and made 17 all-star teams, all with an impressive 15-year stretch.Yet, while he was managing the Cincinnati Reds in 1988, he was found guilty of betting on the game, and was subsequently banned from Major League Baseball. This has kept him from being elected to the Hall of Fame-any ballot listing him as of now is thrown out.Although he denied this at the time, he has since admitted to betting on his team, but only as a standing bet every night to win the game.First, nothing has ever been found to discredit Rose on this point.

This is interesting, as it would seem it hardly served any point besides extra incentive to win. Second, many people are rather unclear as to the official definition of gambling on baseball, as seen on a recent poll on sports writer Joe Posnanski’s blog.Readers were almost completely indifferent to smaller or less “official” bets (for example, a $5 bet with friends about an outcome of a game compared to larger bets with bookies). Additionally, whether the bet was to win or lose the game was also a rather large factor. Rose, again, has said he only bet that his team would win, which should have been his goal anyway.In addition to being redundant, the official banishment only extended officially to the Hall of Fame in 1991, the year Pete Rose was first eligible, making his Hall of Fame status seem especially cruel and vindictive.In any case, Commissioner Giamatti, the man who banned Pete Rose, in the original agreement, gave Rose the ability to apply for reinstatement once a year for the rest of his life, with the intention of reinstating him after several years.However, eight days after the ruling, Giamatti suffered a fatal heart attack. Since then, one of the main arguments against Rose’s reinstatement has been that it would be an injustice to Giamatti’s legacy DESPITE Giamatti’s original intent.